159 related articles for article (PubMed ID: 22710850)
1. Pharmacogenetics of antidepressive drugs: a way towards personalized treatment of major depressive disorder.
Weizman S; Gonda X; Dome P; Faludi G
Neuropsychopharmacol Hung; 2012 Jun; 14(2):87-101. PubMed ID: 22710850
[TBL] [Abstract][Full Text] [Related]
2. [Possibility of a pharmacogenetic approach for prediction and personalized medication in major depressive disorder treatment].
Kato M
Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Apr; 30(2):83-92. PubMed ID: 20491282
[TBL] [Abstract][Full Text] [Related]
3. Neurobiological mechanisms in major depressive disorder.
aan het Rot M; Mathew SJ; Charney DS
CMAJ; 2009 Feb; 180(3):305-13. PubMed ID: 19188629
[No Abstract] [Full Text] [Related]
4. Role of genetic polymorphisms related to neurotransmitters and cytochrome P-450 enzymes in response to antidepressants.
Lee MS
Drugs Today (Barc); 2007 Aug; 43(8):569-81. PubMed ID: 17925888
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacogenetics/pharmacogenomics in psychiatry].
Ueda M; Ishiguro S; Watanabe T; Saeki Y; Shimoda K
Nihon Rinsho; 2010 Jan; 68(1):155-62. PubMed ID: 20077810
[TBL] [Abstract][Full Text] [Related]
6. Stress responsive neurohormones in depression and anxiety.
Ströhle A; Holsboer F
Pharmacopsychiatry; 2003 Nov; 36 Suppl 3():S207-14. PubMed ID: 14677081
[TBL] [Abstract][Full Text] [Related]
7. Serotonin pathway polymorphisms and the treatment of major depressive disorder and anxiety disorders.
Helton SG; Lohoff FW
Pharmacogenomics; 2015; 16(5):541-53. PubMed ID: 25916524
[TBL] [Abstract][Full Text] [Related]
8. Individualized medicine - implementation of pharmacogenetic diagnostics in antidepressant drug treatment of major depressive disorders.
Kirchheiner J; Bertilsson L; Bruus H; Wolff A; Roots I; Bauer M
Pharmacopsychiatry; 2003 Nov; 36 Suppl 3():S235-43. PubMed ID: 14677085
[TBL] [Abstract][Full Text] [Related]
9. DNA Methylation in Major Depressive Disorder.
Pishva E; Rutten BPF; van den Hove D
Adv Exp Med Biol; 2017; 978():185-196. PubMed ID: 28523547
[TBL] [Abstract][Full Text] [Related]
10. Mutant mouse models and antidepressant drug research: focus on serotonin and brain-derived neurotrophic factor.
Gardier AM
Behav Pharmacol; 2009 Feb; 20(1):18-32. PubMed ID: 19179848
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacological characterization and mechanisms of the novel antidepressive- and/or anxiolytic-like substances identified from Perillae Herba].
Tsuji M; Miyagawa K; Takeuchi T; Takeda H
Nihon Shinkei Seishin Yakurigaku Zasshi; 2008 Aug; 28(4):159-67. PubMed ID: 18800619
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomics of antidepressant drugs.
Horstmann S; Binder EB
Pharmacol Ther; 2009 Oct; 124(1):57-73. PubMed ID: 19563827
[TBL] [Abstract][Full Text] [Related]
13. Emerging drugs for major depressive disorder.
Kennedy SH; Rizvi SJ
Expert Opin Emerg Drugs; 2009 Sep; 14(3):439-53. PubMed ID: 19637989
[TBL] [Abstract][Full Text] [Related]
14. Personalized medicine in major depressive disorder -- opportunities and pitfalls.
Miller DB; O'Callaghan JP
Metabolism; 2013 Jan; 62 Suppl 1(0 1):S34-9. PubMed ID: 23021040
[TBL] [Abstract][Full Text] [Related]
15. The usefulness of genotyping cytochrome P450 enzymes in the treatment of depression.
Dubovsky SL
Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):369-79. PubMed ID: 25554071
[TBL] [Abstract][Full Text] [Related]
16. [Mechanism of action of antidepressants and therapeutic perspectives].
Bourin M; David DJ; Jolliet P; Gardier A
Therapie; 2002; 57(4):385-96. PubMed ID: 12422559
[TBL] [Abstract][Full Text] [Related]
17. Recent molecular genetic studies and methodological issues in suicide research.
Tsai SJ; Hong CJ; Liou YJ
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):809-17. PubMed ID: 20977922
[TBL] [Abstract][Full Text] [Related]
18. Relationship of neurotransmitters to the symptoms of major depressive disorder.
Nutt DJ
J Clin Psychiatry; 2008; 69 Suppl E1():4-7. PubMed ID: 18494537
[TBL] [Abstract][Full Text] [Related]
19. Does pretreatment testing for serotonin transporter polymorphisms lead to earlier effects of drug treatment in patients with major depression? A decision-analytic model.
Smits KM; Smits LJ; Schouten JS; Peeters FP; Prins MH
Clin Ther; 2007 Apr; 29(4):691-702. PubMed ID: 17617292
[TBL] [Abstract][Full Text] [Related]
20. HPA-axis regulation at in-patient admission is associated with antidepressant therapy outcome in male but not in female depressed patients.
Binder EB; Künzel HE; Nickel T; Kern N; Pfennig A; Majer M; Uhr M; Ising M; Holsboer F
Psychoneuroendocrinology; 2009 Jan; 34(1):99-109. PubMed ID: 18829172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
